Breakthroughs in gene editing and advanced genetic medicines are not happening because development is easy. They are happening because the need is urgent, and because rare disease has pushed innovators to build new toolsets.
In 2025, the world marked a major milestone when “Baby KJ” Muldoon received the first personalized mRNA-based CRISPR gene editing therapy, developed through a rapid collaboration between academic teams and industry partners, including Danaher companies Aldevron and Integrated DNA Technologies (IDT). The headlines about Baby KJ’s successful treatment weren’t the point for manufacturers like Aldevron and IDT. The real achievement was the blueprint they created: when science, manufacturing, quality, and regulatory alignment move in sync, timelines that once seemed immovable can be compressed.
Manufacturers help innovators translate scientific possibilities into something repeatable, scalable, and ready for the real world. That means building and manufacturing the critical inputs — DNA, RNA, proteins, and enabling technologies — with the rigor required for advanced medicines. It also means partnering early, aligning teams, and bringing disciplined execution to programs that cannot afford delays.
A difficult moment for biotech — and exactly the time to double down
The biotechnology sector is moving through a challenging period. Funding has tightened, uncertainty has increased, and many companies have been forced to narrow pipelines, delay programs, or close altogether. This pressure is especially acute for rare disease programs, which are capital-intensive, technically complex, and nearly impossible to restart once momentum fades.
But, for patients and families, market cycles don’t slow the urgency of disease progression. Scientific breakthroughs don’t lose their importance when funding becomes scarce. That’s why now is the time to double down.
Doubling down does not mean ignoring reality. It means making disciplined choices that keep innovation moving by focusing resources on programs with the strongest rationale, building partnerships that share risk and accelerate learning, and strengthening the manufacturing and quality foundations that allow breakthroughs to reach patients.
Why credible partners matter more as pathways evolve
On February 23, 2026, the FDA took a meaningful step forward for the rare disease community by issuing draft guidance for individualized therapies. The new framework aims to accelerate the development of gene editing and RNA-based treatments for ultra-rare diseases, where traditional randomized controlled trials aren’t feasible due to extremely small patient populations.
The guidance acknowledges a reality that the rare disease field has long faced: conventional development models are not effective for conditions defined by unique or ultra-rare genetic drivers. Under this framework, the FDA outlines how sponsors may generate substantial evidence of effectiveness and safety using alternative approaches, such as well-characterized natural history data, small clinical studies, and other confirmatory evidence aligned to a clear biological mechanism.
This shift has the potential to change what is possible for families waiting on treatments that would otherwise never enter a traditional pipeline. But greater flexibility also raises the bar for execution. Compressed timelines and highly tailored evidence packages demand partners who can move fast without cutting corners — partners with deep experience in advanced modalities, quality systems built for complexity, and the ability to operate confidently in regulatory gray space.
As the FDA aligns regulation more closely with modern biology, the rare disease community will need strong, credible, and experienced collaborators to turn these pathways into real outcomes for patients. That combination — scientific innovation paired with operational excellence — will determine whether this promise translates into durable progress.
Reflecting and recommitting
Rare Disease Day (February 28, 2026) is a moment to reflect — but it should also be a moment to recommit. Rare disease has shaped some of the most important advances in genomic medicine. The next wave of progress will come from the same place: bold science, disciplined execution, and partners who can help turn urgency into reality.
That is the work worth doubling down on — because the impact will reach far beyond rare disease, and because patients cannot wait.
